文献速递血液净化与透析慢性肾脏病

2型糖尿病腹膜透析患者血糖控制与生存的关联:PDOPPS研究

Association between Glycemic Control and Survival in Patients with Type 2 Diabetes on Peritoneal Dialysis: Results from PDOPPS.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-09-18

基于PDOPPS前瞻性队列8国数据,分析8436例腹膜透析至少90天的2型糖尿病患者,发现基线HbA1c>8%与全因死亡风险升高独立相关(HR 1.18)。亚组分析显示年轻、无冠心病、白蛋白正常者风险更高,改善血糖控制至HbA1c≤8%可能带来3年绝对生存获益。

要点

  • 腹膜透析合并2型糖尿病患者HbA1c>8%与全因死亡风险增加18%相关。
  • 年龄<65岁、无冠心病、白蛋白>3.0 g/dl者血糖控制不佳的死亡风险更高。
  • 将HbA1c降至≤8%在年轻患者中3年绝对生存获益可达12%。

核心结论

  • HbA1c>8%与腹膜透析糖尿病患者全因死亡风险升高相关,支持对特定亚组(年轻、无炎症、无冠心病)采用更严格的个体化血糖目标。

研究设计与样本

  • 前瞻性队列研究,纳入8个国家PDOPPS研究中腹膜透析至少90天的2型糖尿病患者,共8436例,平均随访16个月。

主要发现

  • 与HbA1c≤8%相比,HbA1c>8%与全因死亡风险升高相关(HR 1.18,95%CI 1.03-1.35,P=0.02)。
  • 亚组中年龄<65岁(HR 1.28,95%CI 1.05-1.56,P=0.01)、白蛋白>3.0 g/dl(HR 1.25,95%CI 1.07-1.46,P=0.004)、无冠心病(HR 1.24,95%CI 1.06-1.46,P=0.008)、血红蛋白<10 g/L(HR 1.50,95%CI 1.09-2.07,P=0.01)、PD龄<1年(HR 1.22,95%CI 1.03-1.45,P=0.02)风险更高。
  • 3年预测生存优势:HbA1c≤8%较>8%总体绝对获益7%,年轻(<65岁)人群增至12%。
  • 年龄<65岁、白蛋白正常且无冠心病史者绝对生存优势最大,为16%(78% vs 61%)。

临床怎么用

  • 对腹膜透析合并2型糖尿病患者,可考虑将HbA1c≤8%作为个体化血糖控制目标,尤其年轻、无冠心病、白蛋白正常者可能获益更大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Current clinical guidelines for glycemic control in patients on peritoneal dialysis lack a strong evidence base. In patients on peritoneal dialysis with diabetes, HbA1c >8% is associated with increased all-cause mortality. Younger patients with less comorbidity have the greatest potential survival benefit with improved glycemic control. BACKGROUND: Diabetes is the leading cause of kidney failure globally affecting 40% of people receiving peritoneal dialysis (PD). High-quality data on the potential impact of improving glycemic control is needed to inform the current recommendations to individualize HbA 1C targets. METHODS: Data from 8 countries in the prospective cohort Peritoneal Dialysis Outcomes and Practice Patterns Study (2014-2022) were used to assess the association between baseline HbA 1C and all-cause mortality in people with type 2 diabetes on PD for at least 90 days. Cox proportional hazards model adjusted for potential confounders was used to assess the relationship in the whole cohort and subgroups. Using inverse probability weighting, an average treatment effect in the treated analysis further investigated potential implications of improved glycemic control. RESULTS: HbA 1C was measured at least once in 8436 patients during a mean follow-up of 16 months. Compared with HbA 1C ≤8% (Diabetes Control and Complications Trial units), HbA 1C >8% was associated with higher risk of all-cause mortality in the cohort as a whole (hazard ratio [HR] 1.18 P = 0.02 95% confidence interval [CI], 1.03 to 1.35) and within subgroups: age younger than 65 years (HR, 1.28; P = 0.01; 95% CI, 1.05 to 1.56), average albumin >3.0 g/dl (HR, 1.25; P = 0.004; 95% CI, 1.07 to 1.46), no preexisting coronary artery disease (CAD; HR, 1.24; P = 0.008; 95% CI, 1.06 to 1.46), hemoglobin <10 g/L (HR, 1.50; P = 0.01; 95% CI, 1.09 to 2.07), and PD vintage <1 year (HR, 1.22; P = 0.02; 95% CI, 1.03 to 1.45). The projected survival advantage at 3 years for those with HbA 1C ≤8% compared with >8% was 7% overall, increasing to 12% in younger cohorts (age younger than 65 years). The largest predicted absolute survival advantage of 16% (78% versus 61%) was seen in those aged younger than 65 years, with a normal serum albumin level and no history of CAD. CONCLUSIONS: Associations between HbA 1C and mortality argue for tighter individualized targets for patient subgroups (younger, noninflamed, and without established CAD). Our weighted analysis suggests improved glycemic control (reducing HbA 1C to <8%) may result in an absolute reduction in mortality at 3 years of up to 12% in younger cohorts.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Williams JK, Lambie M, Davies S, et al. Association between Glycemic Control and Survival in Patients with Type 2 Diabetes on Peritoneal Dialysis: Results from PDOPPS. Clin J Am Soc Nephrol. 2026. PMID: 42758555. doi:10.2215/CJN.0000001200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。